Waldencast plc
Waldencast stock fell 15.3% after announcing plans to delist from Nasdaq by October 2, 2026, and seek OTC quotation under the new ticker 'MLKM'. The company cited high U.S. listing costs and reduced need for public equity markets. The Nasdaq Composite and S&P 500 also declined, amplifying the selling pressure. The move is seen as a liquidity downgrade, potentially triggering forced selling by institutional funds.
Waldencast (WALD) shares dropped 15.3% premarket after announcing plans to delist from Nasdaq by October 2026, citing high costs and low trading volume. The company, now a single-brand entity post-Obagi Medical sale, may rename to Milk Makeup and trade OTC under 'MLKM'. SEC deregistration is expected to follow.
Souza Cristiano purchased 335,000 indirectly-held shares of Waldencast plc (WALD) at $1.51 ($0.51M total) on 2026-08-28.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning WALD (Waldencast plc). Coverage has skewed bearish: 0 bullish, 0 neutral, and 2 bearish.
Recent WALD coverage spans financial news, market movers and corporate actions.
In the last 30 days, WALD insiders filed 1 SEC Form 4 transaction — 1 purchase ($506K) and no sales. The most active reporter was Souza Cristiano with 1 filing.
Liquidity downgrade and forced selling pressure likely push the stock lower in the short term.
The delisting announcement triggers immediate sell pressure and likely further downside as liquidity evaporates.
Souza Cristiano purchased 335,000 indirectly-held shares of Waldencast plc (WALD) at $1.51 ($0.51M total) on 2026-08-28.
Waldencast's shares experienced a significant decline amidst a positive broader market trend, indicating company-specific issues rather than sector-wide concerns.
WALD's neutral sentiment indicates limited immediate impact.
AlphAI scores every news story that mentions WALD with an AI model for sentiment and relevance, and aggregates insider trades from Waldencast plc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Waldencast stock fell 15.3% after announcing plans to delist from Nasdaq by October 2, 2026, and seek OTC quotation under the new ticker 'MLKM'. The company cited high U.S. listing costs and reduced need for public equity markets. The Nasdaq Composite and S&P 500 also declined, amplifying the selling pressure. The move is seen as a liquidity downgrade, potentially triggering forced selling by institutional funds.
2 min readWaldencast (WALD) shares dropped 15.3% premarket after announcing plans to delist from Nasdaq by October 2026, citing high costs and low trading volume. The company, now a single-brand entity post-Obagi Medical sale, may rename to Milk Makeup and trade OTC under 'MLKM'. SEC deregistration is expected to follow.
1 min readSouza Cristiano purchased 335,000 indirectly-held shares of Waldencast plc (WALD) at $1.51 ($0.51M total) on 2026-08-28.
1 min readU.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 500 points on Monday. The Dow traded up 0.65% to 46,546.82 while the NASDAQ rose 2.32% to 22,789.25. The S&P 500 also rose, gaining, 1.40% to 6,696.44. Communication services shares jumped by 3.1% on ...
4 min readU.S. stock futures were higher this morning, with the Nasdaq futures gaining around 100 points on Monday. Shares of Novo Nordisk A/S ( NYSE:NVO ) fell sharply in today's pre-market trading after Evoke Phase 3 trials data showed that GLP-1 drugs did not demonstrate statistically significant ...
4 min readTransformation efforts drive performance improvements at Obagi Medical with accelerating revenue ...
4 min readNEW YORK, Nov. 14, 2025 ( GLOBE NEWSWIRE ) -- Waldencast plc, ( NASDAQ: WALD ) ( "Waldencast" or the "Company" ) , a global multi-brand beauty and wellness platform, today announced that it had sold its rights to the "Obagi" trademark in Japan to Rohto Pharmaceutical Co., Ltd. ( "Rohto" ) for ...
3 min readU.S. Launch Planned in 2026 and Positions Obagi Medical as a Leading Dermatological Megabrand at the Convergence of Integrated Skincare and Aesthetics While Doubling its Addressable Market U.S. Launch Planned in 2026 and Positions Obagi Medical as a Leading Dermatological Megabrand at the ...
4 min readObagi Medical delivers H1 2025 double-digit growth in its Core Strategic Channels. Novaestiq Acquisition Doubles the Brand's Addressable Market in the U.S.
3 min readWaldencast plc WALD will release earnings results for the second quarter after the closing bell on Monday, Aug. 18. Analysts expect the White Plains, New York-based company to report a quarterly loss at 5 cents per share.
2 min read
